AstraZeneca expressed immense pride in the vaccine but cited a commercial choice.
The emergence of novel coronavirus strains prompted a shift in demand towards newer, upgraded vaccines.
While estimated to have preserved millions of lives during the pandemic, its vaccine also resulted in infrequent, yet occasionally lethal, blood clotting incidents.
In the global effort to alleviate the world from pandemic restrictions, the Covid vaccine was swiftly developed by researchers at the University of Oxford. A process typically spanning a decade was condensed to approximately ten months.
In November 2020, it was hailed as "a vaccine for the world" due to its significantly lower cost and easier storage requirements compared to other Covid vaccines. The pharmaceutical behemoth AstraZeneca had committed to mass production.
Initially, it served as the linchpin of the UK's strategy to navigate out of lockdown.
"It truly made a monumental impact, it was the beacon that guided us out of the crisis that was unfolding at the time, alongside Pfizer's vaccine," remarked Prof Adam Finn, of the University of Bristol.
However, its standing was tarnished as uncommon blood clotting incidents surfaced as a rare adverse effect of the vaccine, prompting the UK to explore alternative options.
In a declaration, AstraZeneca stated: "According to independent assessments, more than 6.5 million lives were preserved in the inaugural year of deployment alone.
"Our endeavors have garnered acknowledgment from governments worldwide and are widely acknowledged as a crucial element in halting the global pandemic."
It noted that the creation of fresh vaccines, tailored to better match the mutated variants of Covid currently in circulation, had resulted in an "excess of updated vaccines" available, leading to a "diminished demand" for its vaccine, which is "no longer in production or distribution".
Prof Finn further remarked: "I believe the withdrawal of the vaccine simply indicates it's no longer efficacious.
"It has transpired that this virus is highly adaptable and has diverged from the original vaccines, rendering them somewhat obsolete, with only the reconfigured vaccines likely in use now."
